Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Monday, November 18th. Analysts expect Cellectar Biosciences to post earnings of ($0.34) per share for the quarter.
Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cellectar Biosciences Stock Performance
Shares of NASDAQ CLRB opened at $2.12 on Tuesday. The firm has a 50 day moving average price of $2.08 and a two-hundred day moving average price of $2.46. The stock has a market cap of $86.01 million, a P/E ratio of -0.84 and a beta of 1.00. Cellectar Biosciences has a 52-week low of $1.82 and a 52-week high of $4.45.
Wall Street Analyst Weigh In
View Our Latest Stock Report on CLRB
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
See Also
- Five stocks we like better than Cellectar Biosciences
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Why Are Stock Sectors Important to Successful Investing?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
- What Investors Need to Know to Beat the Market
- These 3 Active ETFs Beat the S&P 500 Over the Last Five Years
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
